Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year
The opportunity is enormous, but uncertainty remains.
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year
Overview
CRISPR Therapeutics (NASDAQ: CRSP) has been anything but stable this year. Over the past six months, the stock has experienced sharp swings as the market attempts to determine whether CRISPR is becoming a commercial-stage biotech company or a high-risk clinical-stage play.
The answer is somewhere in between.
Details
CRISPR Therapeutics' biggest milestone came in late 2023, when CASGEVY, the gene-editing therapy it developed alongside Vertex Pharmaceuticals (NASDAQ: VRTX), became the first CRISPR-based treatment ever approved by regulators for the treatment of sickle cell disease.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
